GlaxoSmithKline Pharmaceuticals Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Bhushan Akshikar
Chief executive officer
₹66.9m
Total compensation
| CEO salary percentage | 21.7% |
| CEO tenure | 2yrs |
| CEO ownership | n/a |
| Management average tenure | 2.2yrs |
| Board average tenure | 6.7yrs |
Recent management updates
Recent updates
GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates
Nov 01
We Think GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Can Manage Its Debt With Ease
Aug 29The GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) First-Quarter Results Are Out And Analysts Have Published New Forecasts
Aug 05Investors Appear Satisfied With GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Prospects As Shares Rocket 26%
Jun 01With EPS Growth And More, GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Makes An Interesting Case
May 05GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Popularity With Investors Is Clear
Apr 14Revenue Miss: GlaxoSmithKline Pharmaceuticals Limited Fell 5.9% Short Of Analyst Revenue Estimates And Analysts Have Been Revising Their Models
Feb 15Is Now The Time To Put GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) On Your Watchlist?
Jan 18GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Investors Are Less Pessimistic Than Expected
Dec 28Here's Why We Think GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Might Deserve Your Attention Today
Oct 05Is GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Using Too Much Debt?
Sep 12GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Has A Pretty Healthy Balance Sheet
Mar 17Does GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Have A Healthy Balance Sheet?
Sep 02GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Seems To Use Debt Rather Sparingly
Mar 02The GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Share Price Is Up 32% And Shareholders Are Holding On
Mar 20Does GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Have A Place In Your Dividend Portfolio?
Feb 27Declining Stock and Decent Financials: Is The Market Wrong About GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO)?
Feb 06What Type Of Shareholders Make Up GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Share Registry?
Jan 11
GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Shareholders Have Enjoyed A 26% Share Price Gain
Dec 06Earnings Miss: GlaxoSmithKline Pharmaceuticals Limited Missed EPS By 48% And Analysts Are Revising Their Forecasts
Nov 01Tread With Caution Around GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) 1.3% Dividend Yield
Oct 29What Kind Of Shareholders Hold The Majority In GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Shares?
Sep 29If You Had Bought GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Stock A Year Ago, You Could Pocket A 30% Gain Today
Aug 30Is GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Recent Performancer Underpinned By Weak Financials?
Aug 02CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | ₹7b |
| Jun 30 2024 | n/a | n/a | ₹6b |
| Mar 31 2024 | ₹67m | ₹15m | ₹6b |
| Dec 31 2023 | n/a | n/a | ₹5b |
| Sep 30 2023 | n/a | n/a | ₹6b |
| Jun 30 2023 | n/a | n/a | ₹6b |
| Mar 31 2023 | ₹34m | ₹4m | ₹6b |
Compensation vs Market: Bhushan's total compensation ($USD783.16K) is above average for companies of similar size in the Indian market ($USD580.07K).
Compensation vs Earnings: Bhushan's compensation has increased by more than 20% in the past year.
CEO
Bhushan Akshikar
2yrs
Tenure
₹66,885,000
Compensation
Mr. Bhushan Akshikar is Managing Director of GlaxoSmithKline Pharmaceuticals Limited from December 1, 2022. He served as Additional Director of GlaxoSmithKline Pharmaceuticals Limited since March 18, 2021...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD & Executive Director | 2yrs | ₹66.89m | no data | |
| Whole-Time Director & CFO | 2.7yrs | ₹68.92m | no data | |
| Executive Vice President of Human Resources | 4yrs | ₹37.40m | no data | |
| Vice President of Technology | less than a year | no data | no data | |
| VP of Administration & Real Estate and Company Secretary | no data | ₹11.57m | no data | |
| Executive Vice President of Legal | 2.8yrs | no data | no data | |
| Vice President of Ethics & Compliance | 1.8yrs | no data | no data | |
| Executive Vice President of Communications & Government Affairs | 7.7yrs | no data | no data | |
| Executive Vice-President of Regulatory Affairs | no data | no data | no data | |
| Executive Vice-President of Adult Vaccines | 2.4yrs | no data | no data | |
| Executive Vice President of General Medicines | 2yrs | no data | no data | |
| Commercial Head - Paediatric Vaccines | 1.9yrs | no data | no data |
2.2yrs
Average Tenure
Experienced Management: GLAXO's management team is considered experienced (2.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD & Executive Director | no data | ₹66.89m | no data | |
| Whole-Time Director & CFO | 2.7yrs | ₹68.92m | no data | |
| Non-Executive Chairperson | 5.7yrs | ₹3.25m | no data | |
| Independent Director | 2.6yrs | ₹2.65m | no data | |
| Non-Executive Independent Director | 15.4yrs | ₹2.70m | no data | |
| Non Executive Director | 7.7yrs | no data | no data | |
| Non-Executive Independent Director | 14.2yrs | ₹2.70m | no data | |
| Non-Executive Independent Director | 13.1yrs | ₹2.45m | no data | |
| Non-Executive & Independent Director | 4.6yrs | ₹2.45m | no data |
6.7yrs
Average Tenure
68.5yo
Average Age
Experienced Board: GLAXO's board of directors are considered experienced (6.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/28 09:39 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
GlaxoSmithKline Pharmaceuticals Limited is covered by 25 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Shirish Pardeshi | Anand Rathi Shares and Stock Brokers Limited |
| Sarabjit Nangra | Angel Broking Private Limited |
| Prakash Agarwal | Axis Capital Limited |